Canada markets closed

Actinium Pharmaceuticals, Inc. (ATNM)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
9.80-0.05 (-0.51%)
At close: 04:00PM EDT
9.73 -0.07 (-0.71%)
After hours: 07:46PM EDT

Actinium Pharmaceuticals, Inc.

100 Park Avenue
23rd Floor
New York, NY 10017
United States
646 677 3870
https://www.actiniumpharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees49

Key Executives

NameTitlePayExercisedYear Born
Mr. Sandesh C. Seth M.B.A., M.S.Chairman & CEO1.21MN/A1964
Mr. Steven O'Loughlin BSCFO & Corporate Secretary590kN/A1986
Dr. Paul Diamond Esq., Ph.D.Vice President of Patent & Legal CounselN/AN/AN/A
Dr. David GouldSenior Vice President of Corporate Development & Corporate AffairsN/AN/AN/A
Dr. Bernie Cunningham P.M.P., Ph.D.Executive Director of Clinical Supply Chain & Logistics and CMC Project ManagementN/AN/AN/A
Dr. Qing LiangVP & Head of Radiation SciencesN/AN/AN/A
Dr. Avinash Desai M.D.Chief Medical OfficerN/AN/AN/A
Ms. Jenny HsiehChief Strategy OfficerN/AN/AN/A
Ms. Sunitha LakshminarayananSenior VP, Head of CMC & Product DevelopmentN/AN/AN/A
Ms. Elaina HaeuberVP & Head of Clinical OperationsN/AN/AN/A
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, Iomab-B (I-131 apamistamab) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iomab-ACT for GeneTx and cell therapy conditioning, Actimab-A (CD33) and CLAG-M, Actimab-A (CD33) and Venetoclax, and Actimab-A (CD33) and Venetoclax with HMA. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 -SIRPa immunotherapy targeted radiotherapy; AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors; and Immedica pharma for licensed the rights to commercialize Iomab-B. The company is based in New York, New York.

Corporate Governance

Actinium Pharmaceuticals, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 10. The pillar scores are Audit: 8; Board: 9; Shareholder Rights: 6; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.